JDRF is the world's leading not-for-profit supporter of type 1 diabetes research globally, investing over $1.7 billion since 1970, including nearly $160 million into Australian research.
We are working to cure, treat and prevent type 1 diabetes in people of all ages.
We know that the concept of a ‘cure' can mean different things to different people.
If you have just been diagnosed with type 1 diabetes, a cure includes the protection of remaining insulin-producing cells to reduce the likelihood of blood glucose fluctuations and the onset of complications.
If you have type 1 diabetes in your family, or are at high risk of developing type 1 diabetes yourself, a cure means stopping the autoimmune process before it causes harm.
If you have had type 1 diabetes for many years, a cure will restore insulin production, protect it from further immune destruction, and potentially reverse the effects of diabetes-related complications.
Read more about our research pathways.
We have the scale, expertise and relationships to achieve our goal.
We are the only organisation with the scale, expertise and relationships required to translate research into life-changing outcomes for people with type 1 diabetes.
As well as directly funding research, we use our expertise to steer the scientific agenda and engage to brightest scientific minds to identify research gaps and accelerate progress in the most promising research areas.
Key to this is our relationships with a wide range of stakeholders in making research progress and delivering it to those who can benefit. These relationships helped JDRF to speed up the translation of academic research as well as address challenges associated with clinical development of potential type 1 diabetes drugs and devices.
These relationships have enabled JDRF to increase the value of the research dollar. Our international reach combined with our domestic focus actively encourages global collaboration, not just between JDRF funded researchers, but with researchers representing other conditions and medical research organisations as well.